House of Commons Hansard Written Answers for 11 Nov 2008 (pt 0024)

11 Nov 2008 : Column 1048W—continued

11 Nov 2008 : Column 1049W

11 Nov 2008 : Column 1050W

BNF paragraph 8.2.4—Other immunomodulating drugs
Number of prescription items used in the treatment of hepatitis B from BNF section 8.2.4, which were dispensed in the community in England from July 2003 to June 2008^{( 1)}
Thousand
SHA^{( 2,)}^{( )}^{( 3)}	Jul-Dec 2003	2004	2005	2006	2007	Jan-Jun 2008
East Midlands	0.1	0.1	0.1	0.1	0.1	⁽⁴⁾—
East of England	0.1	0.2	0.2	0.1	0.1	⁽⁴⁾—
London	0.1	0.2	0.2	0.2	0.2	0.1
North East	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—
North West	0.2	0.2	0.3	0.2	0.2	0.1
South Central	0.1	0.1	0.2	0.1	0.1	⁽⁴⁾—
South East Coast	0.2	0.3	0.2	0.1	0.1	0.1
South West	0.1	0.1	0.2	0.1	0.2	0.1
West Midlands	0.2	0.3	0.3	0.2	0.2	0.1
Yorkshire and the Humber	⁽⁴⁾—	0.1	0.1	0.1	0.1	⁽⁴⁾—
England	1.0	1.7	1.7	1.3	1.3	0.6
⁽¹⁾ Information at SHA level is only available for the past 60 months. ⁽²⁾ The data have been structured in line with current SHA arrangements. The structure changed during 2006 where the number of SHA reduced. ⁽³⁾ The tables show drugs which may be used to treat hepatitis B, by SHA. ⁽⁴⁾ Indicates 50 or fewer items were dispensed during the period Source: The Prescription Pricing Division of the NHS Business Services Authority (NHSBSA (PPD))

BNF paragraph 5.3.3—Viral hepatitis
Number of prescription items used in the treatment of hepatitis B from BNF section 5.3.3, which were dispensed in the community in England from July 2003 to June 2008^{( 1)}
Thousand
SHA^{( 2,)}^{( )}^{( 3)}	Jul-Dec 2003	2004	2005	2006	2007	Jan-Jun 2008
East Midlands	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—	0.1	0.1
East of England	⁽⁴⁾—	⁽⁴⁾—	0.1	⁽⁴⁾—	0.1	0.1
London	0.1	0.1	0.2	0.5	0.6	0.3
North East	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—
North West	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—	0.1	0.1
South Central	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—	0.1	0.1
South East Coast	⁽⁴⁾—	⁽⁴⁾—	0.1	0.1	0.1	0.1
South West	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—	0.1	0.1	0.1
West Midlands	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—	0.1	0.1
Yorkshire and the Humber	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—	⁽⁴⁾—	0.1	0.1
England	0.1	0.3	0.5	0.9	1.5	1.0
⁽¹⁾ Information at SHA level is only available for the past 60 months. ⁽²⁾ The data have been structured in line with current SHA arrangements. The structure changed during 2006 where the number of SHA reduced. ⁽³⁾ The tables show drugs which may be used to treat hepatitis B, by SHA. ⁽⁴⁾ Indicates 50 or fewer items were dispensed during the period Source: The Prescription Pricing Division of the NHS Business Services Authority (NHSBSA (PPD))

BNF paragraph 5.3.1-HIV infection
Number of prescription items used in the treatment of hepatitis B from BNF section 5.3.1, which were dispensed in the community in England from July 2003 to June 2008^{( 1)}
Thousand
SHA^{( 2,)}^{( )}^{( 3)}	Jul-Dec 2003	2004	2005	2006	2007	Jan-Jun 2008
East Midlands	0.1	0.2	0.2	0.3	0.4	0.2
East of England	0.2	0.4	0.5	0.6	0.8	0.4
London	0.7	1.7	1.9	2.4	3	1.6
North East	0.1	0.2	0.2	0.3	0.2	0.1
North West	0.3	0.5	0.5	0.6	0.7	0.4
South Central	0.1	0.2	0.2	0.3	0.3	0.2
South East Coast	0.1	0.2	0.3	0.4	0.4	0.2
South West	0.1	0.2	0.3	0.4	0.4	0.2
West Midlands	0.3	0.6	0.6	0.7	0.7	0.4
Yorkshire and the Humber	0.1	0.3	0.3	0.4	0.5	0.3
England	2.0	4.5	5.1	6.4	7.4	4.0
⁽¹⁾ Information at SHA level is only available for the past 60 months. ⁽²⁾ The data have been structured in line with current SHA arrangements. The structure changed during 2006 where the number of SHA reduced. ⁽³⁾ The tables show drugs which may be used to treat hepatitis B, by SHA. ⁽⁴⁾ Indicates 50 or fewer items were dispensed during the period Source: The Prescription Pricing Division of the NHS Business Services Authority (NHSBSA (PPD))

The following product list was identified for use in the treatment of hepatitis B. It includes specific brands licensed for the treatment of hepatitis B and drugs that may also be licensed for use in other indications. BNF 55, NHS Choices Map of Medicine and NICE Technology Appraisal 96 have been used to identify the products. The data provided have been aggregated from the following specific brands to the respective BNF category as indicated. It does not include those products used for the prevention of hepatitis B.

BNF Paragraph 8.2.4: Other immunomodulating drugs; includes the products IntronA, Pegasys, Roferon-A and Viraferon. These drugs can also be used in other indications. Other products in this BNF chapter not used in the treatment of hepatitis B have been excluded.

BNF Paragraph 5.3.3: Viral hepatitis; includes the products Baraclude, Hepsera and Sebivo. These drugs are only indicated for use with hepatitis B.

Next Section

Index

Home Page